Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030004/S039

Onyx Liquid Embolic System (Onyx LES)

Ev3 Neurovascular · Decision date Oct 14, 2026

MEDTECHLEDGER EXPLANATIONP030004/S039

What did the FDA approve?

The FDA record for P030004/S039 shows an approval dated 2026-10-14 under the Normal 180 Day Track No User Fee, with the supplement reason listed as Postapproval Study Protocol. The changed item is the protocol for a Real-World Use Surveillance post-approval study for the Onyx Liquid Embolic System; the record states that this protocol was submitted to comply with conditions of approval in the earlier approval order for P030004/S035. The S039 supplement number marks it as a later supplement to the same PMA number, not a new approval of the whole system.

The decision covers the study protocol only. The record does not describe endpoints, patient population, sites, duration, or reporting requirements, and it does not report results or independent evidence of safety or clinical effectiveness. The applicant is Ev3 Neurovascular; specialty is Neurology; product code MFE, device category Agent, injectable, embolic. Those facts are absent from the supplied text and are not supplied here.

FDA approval order statement

Approval of the protocol for the Real-World Use Surveillance post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P030004/S035.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Neurology
Decision date
Oct 14, 2026
FDA change category
Postapproval Study Protocol

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P030004/S039
Regulatory pathway
PMA supplement
Product code
MFE
Decision code
APPR
Decision date
Oct 14, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, injectable, embolic.

Product code
MFE
FDA device class
3

For the original device and its historical approval scope, see PMA P030004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030004 · Original PMA

    ONYX LIQUID EMBOLIC SYSTEM

  2. P030004/S039 received

    Application receipt date recorded by FDA.

  3. P030004/S039 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P030004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030004

Product / regulatory recordCompanyPathwayDecision dateSource
Ev3 NeurovascularPMA approvalJul 21, 2005FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ev3 Neurovascular

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
9775 Toledo Way, Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records